The Patient-Reported Outcomes, Survey, and Population Research (PROSPR) shared resource is a centralized source of expertise in the science of collecting and managing participant-reported outcome (PRO) and behavioral data. These data are important in many treatment trials (e.g., to evaluate the impact of treatment on quality of life and symptoms), survivorship studies, and in cancer prevention research. The PROSPR offers services in 3 areas: research support services, which have seen a 100% increase in utilization over the past 5 years, data support services (12% increase), and fitness and body composition testing (new service in 2011). PROSPR has access to a SQL server, as well as equipment for testing fitness and body composition (Hologic bone densitometer, Biodex for measuring strength, 3 metabolic carts, 3 ECGs, 2 cycle ergometers, 1 treadmill, a perometer, and a bank of 150 actigraphs). In the past 5 years, the PROSPR facility has served 112 investigators in 17 programs. PROSPR has facilitated 47 publications with articles appearing in JAMA and J Clin Oncol. Center members with peer-reviewed funding account for 80% of users, and 32% of total costs are requested from the CCSG. The institution has provided $431,072 in financial support for the shared resource since 2008 for operational costs and for equipment, including an HP server, 3 Dell precision workstations, and 150GT3XE-plus triaxial activity monitors. In addition, the fitness and body composition equipment was purchased by the institution. Over the next 5 years, PROSPR will improve its expertise and expand services in design and data management for computer-assisted data collection (e.g., ecological momentary assessment, computer adaptive testing, and internet-based surveys) and expand its expertise in body composition testing.
PROSPR provides assistance to MD Anderson investigators with collection and assessment of Patient Reported Outcomes, behavioral data, and measures of fitness and body composition. These data are central to cancer prevention and survivorship research, and are increasingly incorporated being into cancer treatment trials.
|Yedururi, Sireesha; Terpenning, Silanath; Gupta, Sanjay et al. (2017) Radiofrequency Ablation of Hepatic Tumor: Subjective Assessment of the Perilesional Vascular Network on Contrast-Enhanced Computed Tomography Before and After Ablation Can Reliably Predict the Risk of Local Recurrence. J Comput Assist Tomogr 41:607-613|
|Montalban-Bravo, G; Huang, X; Jabbour, E et al. (2017) A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31:318-324|
|Tadros, Audree B; Smith, Benjamin D; Shen, Yu et al. (2017) Ductal Carcinoma In Situ and Margins <2?mm: Contemporary Outcomes With Breast Conservation. Ann Surg :|
|Ikoma, Naruhiko; Raghav, Kanwal; Chang, George (2017) An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. Surg Oncol Clin N Am 26:667-687|
|Alhuraiji, Ahmad; Jain, Nitin (2017) Immunofluorescence staining with an antipromyelocytic leukemia antibody for a rapid diagnosis of acute promyelocytic leukemia. Hematol Oncol Stem Cell Ther 10:33-34|
|Lin, Heather Y; Bedrosian, Isabelle; Babiera, Gildy V et al. (2017) Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer 123:2618-2625|
|Rozovski, Uri; Harris, David M; Li, Ping et al. (2017) Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res 15:610-618|
|Masarova, Lucia; Kantarjian, Hagop; Garcia-Mannero, Guillermo et al. (2017) Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. Adv Exp Med Biol 995:73-95|
|Palacios, Cristina; Daniel, Carrie R; Tirado-Gómez, Maribel et al. (2017) Dietary Patterns in Puerto Rican and Mexican-American Breast Cancer Survivors: A Pilot Study. J Immigr Minor Health 19:341-348|
|Gunther, Jillian R; Chadha, Awalpreet S; Shin, Ui Sup et al. (2017) Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. Adv Radiat Oncol 2:455-464|
Showing the most recent 10 out of 10289 publications